|
DUE DILIGENCE FOR INVESTORS
Donawa Lifescience Consulting (DLC) understands investors’ concerns and objectives when considering the viability of new investments. Even if the start-up company’s financial planning is coherent, and the intellectual property protected, companies can fail because of misunderstood regulatory requirements, leading to inappropriate marketing strategies and over-optimistic product authorization timescales.
We can provide a comprehensive due diligence service, covering scientific, regulatory, clinical and GMP aspects of drug development, for both European and US market access. Due diligence reports are tailored to client requirements, and subsequent meetings are held to ensure all investment questions are answered.
If requested by the potential investor, DLC can assist the subject company's understanding of the regulatory requirements, allowing them to resubmit updated information.
DLC associates’ senior level experience in the medical profession, pharmaceutical and medical device industries, as well as in regulatory agencies, provides a unique perspective on scientific, regulatory, clinical and GMP issues.
Please contact us for additional information and assistance.
|
